Cardiotool Linee guida Dislipidemie Archivi - Cardiotool

Ultime notizie

Pneumopatia da COVID-19: il punto di vista del Medico Vascolare. “Position paper” patrocinato dalla SIDV e della SIMV
Pazienti con diabete tipo 2 a maggior rischio di demenza vascolare rispetto ad altre demenze
Studio EMPEROR-Reduced: il vantaggio di Empagliflozin rimane stabile sopra Sacubitril/Valsartan
L’idrossiclorochina è inefficace e dannosa nella cura del COVID-19
Dalla strategia fallimentare alle terapie precoci, dalle cure ai tamponi. Il punto sul Covid19

Linee guida

2019 Guidelines on Dyslipidaemias (Management of) ESC Clinical Practice Guidelines

2019 Guidelines on Dyslipidaemias (Management of) ESC Clinical Practice Guidelines

Nov 13, 2019 Cardiotool Linee guida, Linee guida Dislipidemie Commenti disabilitati su 2019 Guidelines on Dyslipidaemias (Management of) ESC Clinical Practice Guidelines

2019 Guidelines on Dyslipidaemias (Management of) ESC Clinical Practice Guidelines These novel ESC/EAS Guidelines on lipids provide important new advice on patient management, which should enable...

Continua a leggere

AHA: nuovo documento sull’uso degli Omega-3 nel trattamento dell’ipertrigliceridemia

AHA: nuovo documento sull’uso degli Omega-3 nel trattamento dell’ipertrigliceridemia

Ott 14, 2019 Gaetano D'Ambrosio Linee guida, Linee guida Dislipidemie, Linee guida Prevenzione primaria, Novità dalla ricerca, Novità Dislipidemie, Novità Homepage, Novità Prevenzione Primaria Commenti disabilitati su AHA: nuovo documento sull’uso degli Omega-3 nel trattamento dell’ipertrigliceridemia

L’American Heart Association (AHA) ha pubblicato un documento che fa il punto sull’utilizzo degli omega-3 nel trattamento dell’ipertrigliceridemia alla luce della letteratura più...

Continua a leggere

Consensus italiana 2014, diagnosi e trattamento dell’ipertrigliceridemia

Consensus italiana 2014, diagnosi e trattamento dell’ipertrigliceridemia

Ott 09, 2019 Cardiotool Linee guida, Linee guida Dislipidemie Commenti disabilitati su Consensus italiana 2014, diagnosi e trattamento dell’ipertrigliceridemia

Consensus italiana 2014, diagnosi e trattamento dell’ipertrigliceridemia

Continua a leggere

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

Set 04, 2019 Cardiotool Linee guida, Linee guida Dislipidemie Commenti disabilitati su 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease...

Continua a leggere

Nuove linee guida 2018 AHA/ACC per la gestione dell’ipercolesterolemia

Nuove linee guida 2018 AHA/ACC per la gestione dell’ipercolesterolemia

Nov 26, 2018 Gaetano D'Ambrosio Linee guida, Linee guida Dislipidemie, Linee guida Prevenzione primaria, Linee guida Prevenzione Secondaria, Novità dalla ricerca, Novità Dislipidemie, Novità Homepage, Novità Prevenzione Primaria, Novità Prevenzione Secondaria Commenti disabilitati su Nuove linee guida 2018 AHA/ACC per la gestione dell’ipercolesterolemia

Le due maggiori associazioni cardiologiche americane, American College of Cardiology (ACC) e American Heart Association (AHA), in collaborazione con altre Società Scientifiche, hanno rilasciato una...

Continua a leggere

Effetti avversi della terapia con statine: rischi e vantaggi

Effetti avversi della terapia con statine: rischi e vantaggi

Giu 06, 2018 Gaetano D'Ambrosio Linee guida, Linee guida Dislipidemie, Novità dalla ricerca, Novità Dislipidemie, Novità Homepage Commenti disabilitati su Effetti avversi della terapia con statine: rischi e vantaggi

Le statine sono farmaci di indubbia efficacia nella prevenzione cardiovascolare primaria e secondaria, motivo per cui il loro utilizzo si è ampiamente diffuso ed è destinato a coinvolgere un numero...

Continua a leggere

(AACE 2017) American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease.Endocrine practice Vol 23 (Suppl 2) April 2017

(AACE 2017) American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease.Endocrine practice Vol 23 (Suppl 2) April 2017

Giu 12, 2017 Redazione Linee guida Dislipidemie, Linee guida Prevenzione primaria Commenti disabilitati su (AACE 2017) American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease.Endocrine practice Vol 23 (Suppl 2) April 2017

Linne guida degli endocrinologi americani sui target per colesterolo LDL, ApoB..

Continua a leggere

(2016) Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

(2016) Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Nov 21, 2016 Redazione Linee guida, Linee guida Dislipidemie Commenti disabilitati su (2016) Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Interazioni tra le varie statine ed altri farmaci per il sistema cardiovascolare frequentemente utilizzati in associazione. Lo statement dell’American Heart Association

Continua a leggere

(2016) European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

(2016) European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Nov 07, 2016 Redazione Linee guida, Linee guida Dislipidemie, Linee guida Prevenzione primaria, Linee guida Prevenzione Secondaria Commenti disabilitati su (2016) European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Documento di consenso sull’utilizzo degli inibitori del PCSK9 nel trattamento dell’ipercolesterolemia della Società Europea di Cardiologia e della Società Europea dell’Aterosclerosi

Continua a leggere

2016 ESC/EAS Guidelines for the management of dyslipidaemias

2016 ESC/EAS Guidelines for the management of dyslipidaemias

Set 01, 2016 Redazione Linee guida, Linee guida Dislipidemie Commenti disabilitati su 2016 ESC/EAS Guidelines for the management of dyslipidaemias

Continua a leggere

(2016) Colesterolo e rischio cardiovascolare: percorso diagnostico-terapeutico in Italia. Documento di consenso intersocietario ANMCO/ISS/AMD/ANCE/ARCA/FADOI/ GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/ SID/SIF/SIMEU/SIMG/SIMI/SISA

(2016) Colesterolo e rischio cardiovascolare: percorso diagnostico-terapeutico in Italia. Documento di consenso intersocietario ANMCO/ISS/AMD/ANCE/ARCA/FADOI/ GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/ SID/SIF/SIMEU/SIMG/SIMI/SISA

Giu 26, 2016 Redazione Linee guida, Linee guida Dislipidemie, Linee guida Prevenzione primaria, Linee guida Prevenzione Secondaria Commenti disabilitati su (2016) Colesterolo e rischio cardiovascolare: percorso diagnostico-terapeutico in Italia. Documento di consenso intersocietario ANMCO/ISS/AMD/ANCE/ARCA/FADOI/ GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/ SID/SIF/SIMEU/SIMG/SIMI/SISA

Continua a leggere

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

Apr 18, 2016 Redazione Linee guida, Linee guida Dislipidemie Commenti disabilitati su 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents

Continua a leggere

2015 USDA. Scientific Report Dietary Guidelines Advisory Committee

2015 USDA. Scientific Report Dietary Guidelines Advisory Committee

Apr 30, 2015 Redazione Linee guida, Linee guida Dislipidemie, Linee guida Prevenzione primaria Commenti disabilitati su 2015 USDA. Scientific Report Dietary Guidelines Advisory Committee

Continua a leggere

NICE 2014. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease

NICE 2014. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease

Mar 30, 2015 Redazione Linee guida, Linee guida Dislipidemie Commenti disabilitati su NICE 2014. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease

Continua a leggere

2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk

2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk

Mar 29, 2015 Redazione Linee guida, Linee guida Dislipidemie, Linee guida Prevenzione primaria Commenti disabilitati su 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk

Continua a leggere

.

AREE TEMATICHE